Moleculin Biotech, Inc. (MBRX): Cash & Equivalents
$8.88M
As of 2025-12-31
$7.26M
As of 2026-06-30
-41.0%
3-year compound annual growth
-10.2%
5-year compound annual growth
n/m
10-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $8.88M | +107.5% | 2026-03-18, Balance as of period end |
| 2024-12-31 | $4.28M | -81.8% | 2026-03-18, Balance as of period end |
| 2023-12-31 | $23.55M | -45.4% | 2025-03-21, Balance as of period end |
| 2022-12-31 | $43.15M | -39.1% | 2024-03-22, Balance as of period end |
| 2021-12-31 | $70.90M | +367.3% | 2023-03-22, Balance as of period end |
| 2020-12-31 | $15.17M | +41.3% | 2022-03-24, Balance as of period end |
| 2019-12-31 | $10.73M | +50.5% | 2021-03-24, Balance as of period end |
| 2018-12-31 | $7.13M | -7.5% | 2020-03-19, Balance as of period end |
| 2017-12-31 | $7.71M | +54.1% | 2019-02-21, Balance as of period end |
| 2016-12-31 | $5.01M | n/m | 2018-03-28, Balance as of period end |
| 2015-12-31 | $28.1K | n/a | 2017-04-03, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Moleculin Biotech, Inc. (MBRX) | 2025-12-31 | $8.88M | +107.5% |
| Abbott Laboratories (ABT) | 2025-12-31 | $8.52B | +11.9% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $10.21B | -1.3% |
| TherapeuticsMD, Inc. (TXMD) | 2024-12-31 | $5.06M | +16.9% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $7.27B | +122.4% |
| Pfizer Inc (PFE) | 2025-12-31 | $1.14B | +9.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $19.71B | -18.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $93.89M | +10.9% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $14.56B | +10.0% |
Compare MBRX, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗